Skip to main content
SpringerLink
Log in

Kolorektales Karzinom, Mammakarzinom und andere Entitäten

Lebermetastasen - interdisziplinäre Therapie

  • Zertifizierte Fortbildung
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. Abdalla EK et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271-80

  2. Hoffmann K et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17(6):1546-54

  3. Frilling A et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-21

  4. Kassahun WT. Controversies in defining prognostic relevant selection criteria that determine long-term effectiveness of liver resection for noncolorectal nonneuroendocrine liver metastasis. Int J Surg. 2015;24(Pt A):85-90

  5. Luedde T et al. Interdisziplinäre Therapie kolorektaler Lebermetastasen. Gastroenterologe. 2016;11(6):479-88

  6. Jara M et al. Reductions in post-hepatectomy liver failure and related mortality after implementation of the LiMAx algorithm in preoperative work-up: a single-centre analysis of 1170 hepatectomies of one or more segments. HPB (Oxford). 2015;17(7):651-8

  7. Ribero D et al. Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol. 2008;25(2):104-9

  8. Angelsen JH et al. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World J Surg Oncol. 2014;12:127

  9. Qadan M, D'Angelica MI. Extending the Limits of Resection for Colorectal Liver Metastases: Positive Resection Margin and Outcome After Resection of Colorectal Cancer Liver Metastases. J Gastrointest Surg. 2017;21(1):196-8

  10. Abdalla EK et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818-25; discussion 825-7

  11. Adam R et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729-41

  12. van der Poel MJ et al. Multicentre propensity score-matched study of laparoscopic versus open repeat liver resection for colorectal liver metastases. Br J Surg. 2019;106(6):783-9

  13. Martínez-Cecilia D et al. Laparoscopic Versus Open Liver Resection for Colorectal Metastases in Elderly and Octogenarian Patients: A Multicenter Propensity Score Based Analysis of Short- and Long-term Outcomes. Ann Surg. 2017;265(6):1192-1200

  14. Sandström P et al. ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). Ann Surg. 2018;267(5):833-40

  15. Madoff DC et al. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol. 2005;16(6):779-90

  16. van Lienden KP et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol. 2013;36(1):25-34

  17. Abulkhir A et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247(1):49-57

  18. Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg. 2013;257(3):377-82

  19. Nordlinger B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-15

  20. Van Cutsem E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-17

  21. Folprecht G et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38-47

  22. Khoo E et al. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford). 2016;18(6):485-93

  23. Maher B et al. The management of colorectal liver metastases. Clin Radiol. 2017;72(8):617-25

  24. Folprecht G et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311-9

  25. Ychou M et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20(13):4289-97

  26. Zorzi D et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94(3):274-86

  27. Ye LC et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31(16):1931-8

  28. Carrato A et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017;81:191-202

  29. Geissler M et al. mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109). Ann Oncol. 2018;29(Suppl_5):v108

  30. Schwartzberg LS et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240-7

  31. Gruenberger T et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702-8

  32. Rusthoven KE et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572-8

  33. Scorsetti M et al. Stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol. 2014;5(3):190-7

  34. Scorsetti M et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol. 2018;13(1):234

  35. Gillams A et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol. 2015;25(12):3438-54

  36. Nosher JL et al. Non-operative therapies for colorectal liver metastases. J Gastrointest Oncol. 2015;6(2):224-40

  37. Rempp H et al. The current role of minimally invasive therapies in the management of liver tumors. Abdom Imaging. 2011;36(6):635-47

  38. Wu YZ et al. Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol. 2011;17(36):4143-8

  39. Nielsen K et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013;37(6):1340-7

  40. Solbiati L et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265(3):958-68

  41. Ruers T et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619-26

  42. Jiao LR et al. Rapid Induction of Liver Regeneration for Major Hepatectomy (REBIRTH): A Randomized Controlled Trial of Portal Vein Embolisation versus ALPPS Assisted with Radiofrequency. Cancers (Basel). 2019;11(3). pii: E302

  43. Pillai K et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore). 2015;94(9):e580

  44. Liang P et al. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology. 2009;251(3):933-40

  45. Pech M et al. MR-guided interstitial laser thermotherapy of colorectal liver metastases: efficiency, safety and patient survival. Eur J Med Res. 2007;12(4):161-8

  46. Vogl TJ et al. Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. Radiol Med. 2014;119(7):451-61

  47. Scheffer HJ et al. Irreversible Electroporation for Colorectal Liver Metastases. Tech Vasc Interv Radiol. 2015;18(3):159-69

  48. Gruber-Rouh T et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer. 2014;134(5):1225-31

  49. Martin RC 2nd et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649-58

  50. Hendlisz A et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687-94

  51. Wasan HS et al. First-line Selective Internal Radiotherapy Plus Chemotherapy Versus Chemotherapy Alone in Patients With Liver Metastases From Colorectal Cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A Combined Analysis of Three Multicentre, Randomised, Phase 3 Trials. Lancet Oncol. 2017;18(9):1159-71

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar, Technische Universität München, München, Deutschland

    Marcella Steffani,  Daniel Hartmann, Michael W. Müller &  Alexander Novotny

  2. Klinik und Poliklinik für Chirurgie, Ismaninger Str. 22, 81675, München, Deutschland

    Marc Martignoni

  3. Direktor Klinik und Poliklinik für Chirurgie, Ismaninger Strasse 22, 81675, München, Deutschland

    Helmut Friess

Authors
  1. Marcella Steffani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc Martignoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael W. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexander Novotny
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Helmut Friess
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen und im Zusammenhang mit diesem Beitrag keine Interessenkonflikte bestehen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steffani, M., Hartmann, D., Martignoni, M. et al. Lebermetastasen - interdisziplinäre Therapie. InFo Hämatol Onkol 23, 49–58 (2020). https://doi.org/10.1007/s15004-020-8132-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-020-8132-2

Search

Navigation